NYSE · BAX
Healthcare · Medical - Instruments & Supplies
$24.39
Down-$0.34 (-1.37%)
Updated Sep 10, 2026, 6:44 PM
SID Score
5.5/10
Composite research score
Smart Money
59/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
BAX closed at $24.39 after 20 trading sessions, down 9.50% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $24.71 | $25.205 | $24.39 | $24.39 | 5.3M |
| Sep 8, 2026 | $25.59 | $25.75 | $24.66 | $24.86 | 5.91M |
| Sep 4, 2026 | $25.33 | $26.115 | $25.26 | $25.83 | 3.42M |
| Sep 3, 2026 | $25.96 | $26.09 | $25.17 | $25.57 | 4.7M |
| Sep 2, 2026 | $25.55 | $26.05 | $25.48 | $25.70 | 4.17M |
| Sep 1, 2026 | $26.31 | $26.56 | $25.17 | $25.48 | 5.28M |
| Aug 31, 2026 | $25.91 | $26.35 | $25.86 | $26.00 | 3.99M |
| Aug 28, 2026 | $25.99 | $26.31 | $25.785 | $26.13 | 3.96M |
| Aug 27, 2026 | $26.06 | $26.435 | $25.815 | $25.93 | 4.5M |
| Aug 26, 2026 | $26.49 | $26.755 | $26.125 | $26.50 | 5.19M |
| Aug 25, 2026 | $26.43 | $26.50 | $26.01 | $26.29 | 3.79M |
| Aug 24, 2026 | $26.37 | $26.61 | $26.065 | $26.49 | 4.43M |
| Aug 21, 2026 | $26.51 | $26.67 | $26.09 | $26.34 | 4.36M |
| Aug 20, 2026 | $25.90 | $26.78 | $25.90 | $26.41 | 3.53M |
| Aug 19, 2026 | $26.04 | $26.75 | $25.87 | $26.64 | 5.05M |
| Aug 18, 2026 | $26.08 | $26.335 | $25.75 | $25.94 | 6.69M |
| Aug 17, 2026 | $26.47 | $26.47 | $25.865 | $25.91 | 5.85M |
| Aug 14, 2026 | $27.01 | $27.16 | $26.595 | $26.73 | 4.96M |
| Aug 13, 2026 | $27.02 | $27.45 | $26.895 | $27.05 | 6.71M |
| Aug 12, 2026 | $27.20 | $27.40 | $26.64 | $26.95 | 6.88M |
The latest Smart Investors Daily articles mentioning BAX.
BAX research
Company profile and research snapshot.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 31, 2026 | Wells Fargo | Equal-Weight | — |
| Jul 31, 2026 | Stifel | Hold | — |
| Jul 31, 2026 | Citigroup | Neutral | — |
| Jul 31, 2026 | TD Cowen | Hold | — |
| Jul 28, 2026 | UBS | Neutral | — |
No generated briefing is available yet.
Yahoo · Sep 3, 2026
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
Yahoo · Aug 30, 2026
Great stock picks are just the start to building a portfolio that can shelter you through whatever the market brings.
Yahoo · Aug 26, 2026
In recent days, IonQ appointed two new board members, veteran finance executive Dr. Eric Ball and former SkyWater chairman and Samsung North America CEO Timothy Baxter, adding deep capital markets and semiconductor leadership experience to its governance. The combination of Ball’s large-scale financing and M&A track record with Baxter’s chip industry and go-to-market expertise could be important as IonQ integrates SkyWater and scales its merchant quantum supply ambitions. Next, we’ll...
Yahoo · Aug 21, 2026
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BAX.
